Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?

Genes - 10 May 2024

Ganoci Lana, Palić Jozefina, Trkulja Vladimir, Starčević Katarina, Šimičević Livija, Božina Nada, Lovrić-Benčić Martina, Poljaković Zdravka, Božina Tamara

Abstract excerpt

A recently discovered haplotype-CYP2C:TG-determines the ultrarapid metabolism of several CYP2C19 substrates. The platelet inhibitor clopidogrel requires CYP2C19-mediated activation: the risk of ischemic events is increased in patients with a poor (PM) or intermediate (IM) CYP2C19 metabolizer phenotype (vs. normal, NM; rapid, RM; or ultrarapid, UM). We investigated whether the CYP2C:TG haplotype affected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Genotype

Share to Haplotypes

Share to Hemorrhage

Share to Platelet Aggregation Inhibitors

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 38790236
DOI: 10.3390/genes15050607
PMCID: PMC11121599

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is CYP2C Haplotype Relevant for Efficacy and Bleeding Risk in Clopidogrel-Treated Patients?PMID 38790236Read ↗

Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks.Semantic proximity Read ↗

Post-Percutaneous Coronary Intervention CYP2C19 Genotyping: The Potential Role In Identifying Clopidogrel Therapy Related Bleeding RisksSemantic proximity Read ↗

Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances.Semantic proximity Read ↗

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Semantic proximity Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Semantic proximity Read ↗

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsSemantic proximity Read ↗

Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.Semantic proximity Read ↗

Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.Semantic proximity Read ↗

Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery DiseaseSemantic proximity Read ↗

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.